Iclusig 15 MG
Ended Awarded
- Contract number
- 36C24525N0859
- Awardee
-
Takeda Pharmaceuticals America, Inc. UEI ENNFDLWFC6L1
- Awarding agency
-
Veterans Integrated Service Network 5
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $14,197
Award facts
- Contract value 100% obligated
- $14,197.39 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Earth City, MO 63045, USA
Award details come from SAM.gov/FPDS.
About this award
Takeda Pharmaceuticals America, Inc., a foreign-owned biopharmaceutical manufacturer and subsidiary of Takeda Pharmaceutical Company Limited, was awarded a delivery order on July 31, 2025, for ICLUSIG 15 mg (ponatinib), an oncology medication, with a ceiling value of $14,197.39. This firm fixed-price delivery order was issued without a small business set-aside and is set to be completed by August 5, 2025. The contract will be performed in Earth City, Missouri, and is funded by Veterans Integrated Service Network 5 (VISN 5), a civilian component of the Department of Veterans Affairs responsible for delivering healthcare services to veterans.
This delivery order is placed against Takeda's existing Blanket Purchase Agreement valued at $123.5 million through the National Acquisition Center, which is specifically designed to streamline the procurement of ICLUSIG for VA medical facilities. Takeda also maintains a substantially larger Federal Supply Schedule contract worth approximately $2.9 billion covering pharmaceuticals and related products through September 2030. These contracting vehicles enable VISN 5 and other VA entities to efficiently acquire specialized cancer treatments for veteran populations, reflecting the company's established role as a critical supplier of oncology medications to the federal healthcare system.
Quick answers
Who was awarded contract 36C24525N0859?
36C24525N0859 was awarded to Takeda Pharmaceuticals America, Inc. by Veterans Integrated Service Network 5 (Veterans Health Administration) on July 31, 2025.
How much is contract 36C24525N0859 worth?
The government has obligated $14,197 on 36C24525N0859.
Is contract 36C24525N0859 an order under another contract?
Yes. 36C24525N0859 is a delivery order under 36F79718D0586, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C24525N0859 competed?
The extent of competition for 36C24525N0859 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award